<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01559727</url>
  </required_header>
  <id_info>
    <org_study_id>GL-2011-29</org_study_id>
    <nct_id>NCT01559727</nct_id>
  </id_info>
  <brief_title>Dose-comparison Study of Prednisone in Heart Failure</brief_title>
  <official_title>Randomized Dose-comparison Study of Prednisone in Patients With Symptomatic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hebei Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the efficacy of three doses of prednisone, a
      glucocorticoid, in treatment of patients with symptomatic heart failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart failure is a leading cause of cardiovascular morbidity and mortality in the world. Most
      patients with acute symptomatic heart failure are admitted with fluid overload. Intravenous
      loop diuretics are an essential component of current treatment in such patients. Newly
      emerging evidence showed that glucocorticoids could potentiate natriuretic peptides' action
      by upregulating the expression natriuretic peptide receptor A (NPR-A) in the kidney, and
      produce a potent diuresis. Therefore, the investigators designed this nonblinded, randomized
      dose comparison study to compare the efficacy of prednisone at 15, 30 and 60 mg/day in
      patients with in symptomatic heart failure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Daily urinary volumes</measure>
    <time_frame>10 days</time_frame>
    <description>Daily urinary volumes will be monitored for 10 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary sodium excretion</measure>
    <time_frame>10 days</time_frame>
    <description>Daily sodium exretions will be assessed at baseline, day 5 and day 10.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The effect of prednisone on renin angiotensin aldosterone system.</measure>
    <time_frame>10 days</time_frame>
    <description>The effect of prednisone on patients' renin angiotensin aldosterone system, such as renin activity, plasma Ang I, plasma Ang II, and plasma aldosterone will be will be assessed on baseline, day 5 and day 10.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The patients with symptomatic heart failure were treated with standard treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15 mg prednisone group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients with symptomatic heart failure are treated with prednisone at dose of 15 mg/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg prednisone group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients with symptomatic heart failure are treated with prednisone at dose of 30 mg/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>60 mg prednisone group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients with symptomatic heart failure are treated with prednisone at dose of 60 mg/day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>The patients with symptomatic heart failure are treated with prednisone at dose of 15 mg/day.</description>
    <arm_group_label>15 mg prednisone group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>The patients with symptomatic heart failure are treated with prednisone at dose of 30 mg/day</description>
    <arm_group_label>30 mg prednisone group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>The patients with symptomatic heart failure are treated with prednisone at dose of 60 mg/day</description>
    <arm_group_label>60 mg prednisone group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hospitalized for symptomatic heart failure

          -  dyspnea at rest or with minimal activity

          -  NT-proBNP &gt; 1000pg/ml

          -  LVEF â‰¤ 40%

        Exclusion Criteria:

          -  any condition (other than CHF) that could limit the use of prednisone;

          -  acute decompensated heart failure

          -  active myocarditis

          -  obstructive or restrictive cardiomyopathy

          -  cardiac surgery within previous 3 months

          -  acute coronary syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kunshen Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Hospital of Hebei Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The First Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050031</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <zip>050031</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2012</study_first_submitted>
  <study_first_submitted_qc>March 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2012</study_first_posted>
  <last_update_submitted>August 27, 2013</last_update_submitted>
  <last_update_submitted_qc>August 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hebei Medical University</investigator_affiliation>
    <investigator_full_name>Kun-shen Liu M.D.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>heart failure</keyword>
  <keyword>diuresis</keyword>
  <keyword>prednisone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

